_PRIVATE_LIMITED.webp)
Biogentek Bg I Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 02-12-2024
- Paid Up Capital ₹ 0.10 M
as on 02-12-2024
- Company Age 26 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.47 Cr
as on 02-12-2024
- Satisfied Charges ₹ 8.80 M
as on 02-12-2024
- Revenue 4.51%
(FY 2020)
- Profit 61.05%
(FY 2020)
- Ebitda 83.17%
(FY 2020)
- Net Worth 27.08%
(FY 2020)
- Total Assets 1.44%
(FY 2020)
About Biogentek Bg I
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.47 Cr. The company has closed loans amounting to ₹8.80 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Gulati and Neeraj Pandey serve as directors at the Company.
- CIN/LLPIN
U74130DL1998PTC093006
- Company No.
093006
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Mar 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Biogentek Bg I?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Gulati  | Director | 13-Mar-1998 | Current |
| Neeraj Pandey | Director | 13-Mar-1998 | Current |
Financial Performance and Corporate Structure Insights of Biogentek Bg I.
Biogentek Bg I Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 4.51% increase. The company also saw a substantial improvement in profitability, with a 61.05% increase in profit. The company's net worth Soared by an impressive increase of 27.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biogentek Bg I?
In 2020, Biogentek Bg I had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 21 Feb 2024 | ₹1.74 M | Open |
Others Creation Date: 20 Oct 2023 | ₹0.90 M | Open |
Hdfc Bank Limited Creation Date: 29 Jun 2023 | ₹0.70 M | Open |
How Many Employees Work at Biogentek Bg I?
Biogentek Bg I has a workforce of 13 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biogentek Bg I, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biogentek Bg I's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
